Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1962 1
1963 1
1965 1
1966 2
1967 2
1968 4
1969 1
1970 1
1972 1
1973 1
1974 5
1975 6
1976 5
1977 2
1978 3
1979 1
1981 5
1982 2
1983 3
1984 10
1985 15
1986 19
1987 23
1988 13
1989 24
1990 19
1991 30
1992 14
1993 15
1994 10
1995 25
1996 14
1997 25
1998 19
1999 14
2000 20
2001 19
2002 29
2003 40
2004 45
2005 42
2006 60
2007 74
2008 78
2009 122
2010 113
2011 123
2012 115
2013 115
2014 148
2015 134
2016 169
2017 145
2018 114
2019 146
2020 212
2021 209
2022 197
2023 192
2024 212
2025 194

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,086 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Felip E, et al. Among authors: chen ym. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20. Lancet. 2021. PMID: 34555333 Clinical Trial.
Gut butyrate-producers confer post-infarction cardiac protection.
Chen HC, Liu YW, Chang KC, Wu YW, Chen YM, Chao YK, You MY, Lundy DJ, Lin CJ, Hsieh ML, Cheng YC, Prajnamitra RP, Lin PJ, Ruan SC, Chen DH, Shih ESC, Chen KW, Chang SS, Chang CMC, Puntney R, Moy AW, Cheng YY, Chien HY, Lee JJ, Wu DC, Hwang MJ, Coonen J, Hacker TA, Yen CE, Rey FE, Kamp TJ, Hsieh PCH. Chen HC, et al. Among authors: chen ym. Nat Commun. 2023 Nov 9;14(1):7249. doi: 10.1038/s41467-023-43167-5. Nat Commun. 2023. PMID: 37945565 Free PMC article.
Design of customized coronavirus receptors.
Liu P, Huang ML, Guo H, McCallum M, Si JY, Chen YM, Wang CL, Yu X, Shi LL, Xiong Q, Ma CB, Bowen JE, Tong F, Liu C, Sun YH, Yang X, Chen J, Guo M, Li J, Corti D, Veesler D, Shi ZL, Yan H. Liu P, et al. Among authors: chen ym. Nature. 2024 Nov;635(8040):978-986. doi: 10.1038/s41586-024-08121-5. Epub 2024 Oct 30. Nature. 2024. PMID: 39478224 Free PMC article.
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Felip E, et al. Among authors: chen ym. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. Epub 2025 May 30. J Clin Oncol. 2025. PMID: 40446184 Clinical Trial.
Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses.
Ma CB, Liu C, Park YJ, Tang J, Chen J, Xiong Q, Lee J, Stewart C, Asarnow D, Brown J, Tortorici MA, Yang X, Sun YH, Chen YM, Yu X, Si JY, Liu P, Tong F, Huang ML, Li J, Shi ZL, Deng Z, Veesler D, Yan H. Ma CB, et al. Among authors: chen ym. Cell. 2025 Mar 20;188(6):1693-1710.e18. doi: 10.1016/j.cell.2024.12.031. Epub 2025 Feb 7. Cell. 2025. PMID: 39922191 Free PMC article.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Sun Y, et al. Among authors: chen ym. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27. Lancet Oncol. 2016. PMID: 27686945 Clinical Trial.
3,086 results